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Abstract: During the menopausal transition, women experience a number of symptoms due 
to declining estrogen levels, including vasomotor symptoms and vulvar and vaginal atrophy 
(VVA). Unlike vasomotor symptoms, vaginal dryness and dyspareunia, the main symptoms of 
VVA, typically worsen without treatment and can significantly impact the quality of life. Up 
to 60% of postmenopausal women may be affected by VVA, but many women unfortunately 
do not seek treatment due to embarrassment or other factors. After 20+ years in development, 
ospemifene (Osphena™) was approved by the US Food and Drug Administration in 2013 for 
treatment of moderate-to-severe dyspareunia associated with VVA due to menopause. As the 
first non-hormonal alternative to estrogen-based products for this indication, the approval of 
ospemifene represents a significant milestone in postmenopausal women’s health. Ospemifene 
is a non-steroidal estrogen receptor agonist/antagonist, also known as a selective estrogen recep-
tor modulator (SERM), from the same chemical class as the breast cancer drugs tamoxifen and 
toremifene. Unlike other selective estrogen receptor modulators, ospemifene exerts a strong, 
nearly full estrogen agonist effect in the vaginal epithelium, making it well suited for the treat-
ment of dyspareunia in postmenopausal women. Results of Phase III clinical trials showed that 
ospemifene significantly improved the vaginal maturation index (decreased parabasal cells and 
increased superficial cells), decreased vaginal pH, and decreased severity of the self-identified 
most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. Long-term 
safety studies revealed that 60 mg ospemifene given daily for 52 weeks was well tolerated and 
was not associated with any endometrium or breast-related safety concerns. This review discusses 
the preclinical and clinical data supporting the use of ospemifene for the treatment of dyspareunia 
associated with VVA due to menopause and provides an overview of its clinical safety.
Keywords: genitourinary syndrome of menopause, SERM, sexual dysfunction
Introduction
Ospemifene is an estrogen receptor agonist/antagonist, also known as a selective 
estrogen receptor modulator (SERM), from the same chemical class (triphenylethyl-
enes) as tamoxifen and toremifene, both of which are used in the treatment of breast 
cancer. Ospemifene is, in fact, one of the major metabolites of toremifene. After over 
20 years in development, ospemifene was approved in early 2013 by the US Food 
and Drug Administration (FDA) for the treatment of moderate-to-severe dyspareunia 
associated with vulvar and vaginal atrophy (VVA) due to menopause. The latest ter-
minology endorsed by the North American Menopause Society and the International 
Society for the Study of Women’s Sexual Health replaces use of the term VVA with 
genitourinary syndrome of menopause (GSM). As the first non-hormonal treatment 
for dyspareunia, the approval of ospemifene, sold under the trade name Osphena™, 
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  represents a   significant milestone in postmenopausal 
women’s health. The complete developmental history of 
ospemifene is discussed in a recently published book1 as well 
as a recent review article in the journal Steroids.2 Prior to the 
approval of ospemifene, the only FDA-approved treatments 
for dyspareunia contained estrogen, which when taken orally 
has been associated with an increased risk of breast cancer3 
and other potentially serious complications4–6 in large clinical 
trials of hormone replacement therapy. Figure 1 shows the 
chemical structures of ospemifene and its known metabolites 
that have been detected in vivo.7
The precipitous decline in the use of estrogen-based thera-
pies for menopausal symptoms following the results of the 
Women’s Health Initiative trials of estrogen plus progestin5 
and estrogen alone8 created an unmet medical need for an 
effective, non-hormonal alternative to estrogen for treating the 
symptoms of VVA. While over-the-counter moisturizers and 
lubricants can bring temporary relief and are recommended for 
postmenopausal women experiencing mild symptoms,9 they 
do not treat the underlying condition and are generally ineffec-
tive for women experiencing moderate-to-severe symptoms.10 
Uniquely, among the FDA-approved SERMs tamoxifen, 
toremifene, raloxifene, and   bazedoxifene, which is approved 
as a single agent only in Europe, ospemifene exerts a strong, 
beneficial estrogen agonist effect on the vaginal epithelium, 
a property that was first observed in Phase I clinical trials.11 
The recognition of ospemifene’s strong estrogenic effects in 
the vagina ultimately led to its development for the treatment 
of dyspareunia rather than postmenopausal osteoporosis or 
breast cancer chemoprevention, which were the originally 
targeted indications.
Dyspareunia, or painful sexual intercourse, along with 
vaginal dryness, itching and incontinence, are the major 
symptoms of VVA, also known as atrophic vaginitis, which 
is a common condition in postmenopausal women charac-
terized by thinning of the vaginal epithelium and atrophy 
of the vulva, vagina, and urinary tract.12 The symptoms of 
VVA are chronic and progressive without treatment in most 
postmenopausal women, eventually leading to the deterio-
ration of urogenital health and sexual dysfunction,13 which 
can in turn adversely affect postmenopausal women physi-
cally, psychologically, and socially.14 Approximately 60% 
of postmenopausal women who have never been treated 
with hormone therapy suffer from VVA12,15,16 and 30% of 
women who experience dyspareunia and/or vaginal dryness 
do not report their symptoms to their physicians.12,13,15,17 
These symptoms are a result of the declining estrogen 
level seen in perimenopause and postmenopause, which 
Figure 1 Metabolism of ospemifene in humans following a single oral dose of [3H]-ospemifene.
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leads to changes in the cellular composition of the vaginal 
epithelium as well as vaginal pH.10 One popular measure 
of VVA is what is known as the vaginal maturation index. 
The vaginal maturation index measures the ratios of the 
different cell types in the vaginal epithelium. Increases in 
superficial and intermediate cells and a decrease in para-
basal cells indicate an improvement in VVA. Vaginal pH 
is normally acidic in premenopausal women, which helps 
keep microbial growth in check, thereby preventing infec-
tion. During the menopausal transition, pH levels begin to 
increase, which can then lead to an increase in yeast and 
urinary tract infections.18 Effective treatment of VVA, as 
with ospemifene or an estrogen-based therapy, leads to 
a decrease in vaginal pH. Thinning of the vaginal wall, 
reduced natural lubrication due to vaginal dryness, reduced 
tissue elasticity, and a shortening and narrowing of the 
vagina can lead to dyspareunia.19
With respect to the safety and efficacy of ospemifene in 
the treatment of dyspareunia associated with VVA due to 
menopause, this review discusses: (1) the preclinical effects 
of ospemifene in the vagina in the ovariectomized rat model 
of menopause; (2) the efficacy of ospemifene in treating VVA 
due to menopause in clinical trials as assessed by improve-
ment in the vaginal maturation index, decrease in vaginal 
pH, and improvement in self-identified most bothersome 
symptom; and (3) the overall safety profile of ospemifene 
in clinical trials.
Preclinical studies
The effects of ospemifene on vaginal weight and epithelial 
height were examined in three studies utilizing the ovariecto-
mized rat model of menopause.20,21 In the first study, groups of 
rats were treated with three different doses (10 mg/kg, 30 mg/kg,   
and 100 mg/kg orally) of ospemifene daily for 2–4 weeks 
and compared to rats treated with raloxifene 10 mg/kg, 
17-α-ethinyl estradiol (EE2) 100 µg/kg, or control (no treat-
ment). When compared to the control rats, all three doses of 
ospemifene at both two and four weeks of treatment resulted 
in significantly increased vaginal weight and epithelial height 
that did not significantly differ from rats treated with EE2, 
which was suggestive of a full estrogen agonist effect. The 
effects of ospemifene on vaginal epithelial height were main-
tained up to 2 weeks after cessation of dosing.21 In contrast, 
raloxifene produced increases in vaginal weight and epithelial 
height only one-half and one-tenth that of EE2, respectively.20 
This result was not unexpected because raloxifene has not 
been shown to have any meaningful effects on the vaginal 
epithelium.22 In agreement with earlier studies,23 ospemifene 
was found to have a partial estrogen agonist effect on uterine 
weight, similar to raloxifene.21
Utilizing the same ovariectomized rat model of 
menopause, the dose response effects of both ospemifene 
and its main metabolite 4-hydroxyospemifene on vaginal 
weight and epithelial height were evaluated and compared 
to the synthetic estrogen EE2 in two additional experiments. 
4-Hydroxyospemifene is by far the most common metabolite 
produced in vivo, followed by 4′-hydroxyospemifene and the 
carboxylated metabolites, which represent only 1%–2% of 
total ospemifene (Figure 1).7 Different groups of rats were 
given a range of doses of ospemifene (0.01 mg/kg, 0.1 mg/kg,   
0.3 mg/kg, 1 mg/kg, 3 mg/kg, and 10 mg/kg) and its metabo-
lite (0.01 mg/kg, 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) daily 
for 2 weeks compared to a fixed dose of EE2 (100 µg/kg), all 
of which were administered orally. With respect to vaginal 
epithelial height, the half maximal effective doses (ED50) 
of ospemifene and 4-hydroxyospemifene were found to be 
0.39 mg/kg and 0.28 mg/kg, respectively, while the calcu-
lated ED50 values for vaginal weight were 0.48 mg/kg and 
4.6 mg/kg, respectively, for ospemifene and its metabolite. 
A clear dose response effect of ospemifene was observed, 
with all doses but the lowest dose producing a significant 
increase in vaginal epithelial height, and the three highest 
doses causing significant increases in vaginal weight com-
pared to ovariectomized control rats. Only the highest dose 
of 4-hydroxyospemifene produced a significant increase in 
vaginal weight. The maximal effect of ospemifene on vaginal 
epithelial height was nearly equivalent to EE2, again sug-
gesting a full estrogen agonist effect, while the effect of the 
metabolite was suggestive of a partial agonist. Histological 
evaluation revealed that ospemifene treatment resulted in 
increased thickness, mucification, and vacuolization of the 
vaginal luminal epithelium,21 while missing vacuoles and 
only minor increases in mucification were observed with 
raloxifene treatment.20
Two additional studies were performed to specifically 
evaluate the effects of ospemifene on vaginal histology 
in the ovariectomized rat model of menopause.21 The first 
of these was a pilot study in which ospemifene was given 
orally or by vaginal suppository daily for 14 days at a 
dose of 1 mg/kg and compared to orally administered EE2 
(100 µg/kg). Ospemifene, whether given orally or by sup-
pository, increased the thickness of the vaginal epithelium 
and increased expression of the progesterone receptor (PR) 
in the epithelium as well as the underlying elastic (lamina 
propria) and muscular (lamina muscularis) tissue layers of 
the vagina in a manner similar to EE2. To confirm the results Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
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of the pilot study, a second study with the same design was 
conducted examining the effects of ospemifene compared 
to EE2 on the vaginal epithelium and PR expression. Again, 
regardless of the route of drug administration, orally or 
locally, the effects of ospemifene on the thickness of the 
vaginal epithelium and PR expression in the epithelium and 
underlying tissue layers were virtually equivalent to EE2, 
confirming a full estrogen agonist effect. The only observed 
difference between ospemifene and EE2 was with respect to 
cornification of the vaginal epithelium, which was absent in 
the ospemifene-treated rats.21
Clinical studies
Phase I
Two early Phase I clinical trials of ospemifene were con-
ducted to evaluate the safety, tolerability, pharmacokinetics, 
and pharmacodynamics of ospemifene following single oral 
doses in male volunteers and repeated daily oral dosing for 
12 weeks in healthy postmenopausal women.11,24 The latter 
trial was a randomized, placebo-controlled, double-blind 
study performed in 40 healthy postmenopausal women in 
order to define a safe and effective dose range for Phase II 
studies.11 Women in this study were randomized to receive 
daily doses of placebo or ospemifene at doses of 25 mg, 
50 mg, 100 mg, or 200 mg for 12 weeks. At each dose level, 
a total of ten subjects were randomly assigned to receive 
placebo (two subjects) or ospemifene (eight subjects). In 
addition to standard laboratory and adverse event monitor-
ing, the following parameters were evaluated: (1) estrogen-
responsive hormonal markers, (2) estrogen-related changes 
in the endometrium, (3) changes in the vaginal maturation 
index (parabasal, intermediate, and superficial cells of the 
vaginal epithelium), and (4) clinical evaluations of vasomotor 
symptoms.
The results of this study showed that ospemifene was 
well tolerated and caused no hematologic, hepatic, or renal 
abnormalities. At doses higher than 100 mg/day, ospemifene 
caused significant increases in serum follicle-stimulating hor-
mone, which is an indicator of estrogenic pituitary feedback, 
but no changes in serum estradiol or luteinizing hormone 
were observed. With respect to the vaginal maturation index, 
all study subjects had an atrophic vaginal epithelium at 
baseline. All doses of ospemifene exerted a clear estrogenic 
effect on the vaginal epithelium as shown by significant 
decreases in the percentages of parabasal cells and significant 
increases in the percentages of superficial cells compared 
to placebo. Regarding endometrial safety, no clinically 
significant changes in endometrial thickness as assessed by 
transvaginal ultrasound were observed at any ospemifene 
dose level, and only minimal proliferative changes were 
seen mostly at the 100 mg and 200 mg doses. No incidences 
of endometrial hyperplasia or bleeding were observed at 
any dose. Although no significant changes in menopausal 
symptoms were observed, there was a tendency for these 
symptoms to decrease at the lower doses and increase at the 
higher doses.11
Phase II clinical trials
Results from the repeated-dose Phase I pilot study in 
healthy postmenopausal women indicated that the appro-
priate ospemifene dose range was between 25 mg/day and 
100 mg/day, as doses 100 mg would avoid some adverse 
estrogenic side effects while maintaining beneficial estrogenic 
effects, especially in the vaginal epithelium. Two Phase II stud-
ies of ospemifene were conducted employing the lower dose 
range, one of which was a placebo-controlled trial25–27 and one 
that employed raloxifene as an active SERM comparator.28,29 
In addition to the treatment of VVA, other targeted indications 
evaluated during the Phase II development of ospemifene 
included postmenopausal osteoporosis, treatment of meno-
pausal symptoms, and cardiovascular disease.
Placebo-controlled, double-blind trial 
in postmenopausal women
This first Phase II study was performed in a total of 160 
healthy postmenopausal women who were randomized to 
receive placebo or ospemifene at 30 mg/day, 60 mg/day, 
or 90 mg/day taken with food.25–27 A separate Phase I study 
conducted to assess the effect of food on the oral bioavail-
ability of ospemifene showed that administration of the drug 
with food increased both maximum concentration and area 
under the concentration–time curve by two to three times that 
seen when given in the fasted state.30 In addition to standard 
safety laboratory assessments and adverse event monitoring, 
endometrial safety was thoroughly monitored by measuring 
endometrial thickening, histologic examination of endome-
trial biopsies, and Ki-67 staining to evaluate endometrial 
proliferation.26 Potential efficacy markers assessed in this 
study included serum lipids (low-density lipoprotein, high-
density lipoprotein, total cholesterol, and triglycerides) and 
vascular markers to evaluate cardiovascular disease treatment 
potential,27 serum and urinary bone markers to assess bone 
turnover,25 vaginal maturation index to assess the potential 
treatment of VVA, and the Kupperman index to assess 
the potential treatment of menopausal symptoms.26 The 
Kupperman index is a numerical index that scores eleven Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
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different menopausal symptoms, including hot flashes, 
insomnia, nervousness, vertigo, headache, and heart palpita-
tions. Each symptom is scored on a scale from 0 to 3, with 0 
being no symptoms and 3 being the most severe.
Ospemifene compared to raloxifene
The design of this Phase II study was similar to the placebo-
controlled study, except that raloxifene was included as 
an active comparator used in place of the placebo.26,29 At 
the time this study was conducted, raloxifene had already 
been FDA-approved for the prevention31 and treatment32 
of postmenopausal osteoporosis. This 12-week, double-
blind, randomized trial included a total of 118 healthy 
postmenopausal women randomly assigned to treat-
ment with either ospemifene (30 mg/day, 60 mg/day, or 
90 mg/day) or raloxifene (60 mg/day). The goals of this 
study were to: (1) evaluate the effects of ospemifene 
compared to raloxifene on hormonal status, serum lipids, 
genital tract, and tolerability in postmenopausal women;29 
and (2) assess the effects of ospemifene on biochemical 
markers of bone turnover in postmenopausal women com-
pared to raloxifene,28 which was an approved treatment and 
preventive agent for postmenopausal osteoporosis. Safety 
and efficacy evaluations in this study were similar to the 
placebo-controlled Phase II study.
Summary of Phase II clinical trials results
In these Phase II studies, ospemifene was again well toler-
ated, and routine safety assessments indicated no safety 
issues.26,29 Similar to observations from the Phase I repeated-
dose pilot study, results from the Phase II studies showed that 
ospemifene had significant, beneficial estrogenic effects on the 
vaginal maturation index. In the placebo-controlled Phase II   
study, ospemifene exerted a clear estrogenic effect on the 
vaginal epithelium at all doses as assessed by the percent 
change in parabasal, intermediate, and superficial cells of 
vaginal smears. Parabasal cells were significantly decreased, 
while ospemifene treatment produced significant increases in 
intermediate and superficial cells compared to placebo at all 
doses except for superficial cells at the 30 mg dose.26 Similar 
results were observed in the Phase II study that compared 
ospemifene to raloxifene. Decreases in parabasal cells and 
increases in intermediate and superficial cells were seen at 
all doses of ospemifene, while no meaningful changes were 
observed with raloxifene treatment. Significant differences 
between the three ospemifene doses and raloxifene were 
demonstrated, except for parabasal cells at the 60 mg dose.29 
Overall, results from the Phase I and Phase II studies clearly 
demonstrated the potential benefits of ospemifene in the 
treatment of VVA due to menopause.
Phase III clinical trials
Based on the results obtained from the Phase I and Phase II 
trials, the treatment of postmenopausal VVA was selected 
as the target indication for the Phase III development of 
ospemifene. This selection was based on the fact that: (1) the 
clinical data were clear, compelling, and consistent with 
objective clinical indicators such as the vaginal maturation 
index; (2) the FDA had already established clear guide-
lines for obtaining approval for the treatment of VVA; (3) 
the Phase II studies showed that the dose of ospemifene 
needed to treat VVA would be at the low end of the tested 
dose range, thus minimizing potential side effects; (4) there 
were no existing drugs in the same class as ospemifene 
that had been approved for the treatment of VVA, which 
meant that ospemifene would not need to be compared to 
any existing medications in Phase III; and (5) the number 
of postmenopausal women suffering from the symptoms of 
VVA was large and underserved by existing products.1
A total of five Phase III trials of ospemifene were con-
ducted. The first pivotal Phase III study33 evaluated the effi-
cacy of ospemifene at doses of 30 mg and 60 mg in treating 
VVA as assessed by four co-primary endpoints: increase in 
superficial cells and decrease in parabasal cells of the vaginal 
maturation index, decrease in vaginal pH, and improvement 
in the self-identified most bothersome symptom, which 
could include vaginal dryness, itching, dysuria, bleeding, or 
dyspareunia. The second pivotal Phase III trial, which was 
actually composed of two identically designed studies focus-
ing on the treatment of dyspareunia34 and vaginal dryness,35 
respectively, evaluated the efficacy of 60 mg ospemifene 
at the same four co-primary endpoints. Long-term safety 
and efficacy were the focus of the last two Phase III clinical 
trials, one that was a 40-week extension of the first pivotal 
12-week Phase III study36,37 and one that was a dedicated 
52-week long-term safety study evaluating daily dosing with 
60 mg ospemifene.38
First pivotal Phase III study
This first double-blind, randomized, placebo-controlled 
Phase III trial of ospemifene included 826 postmenopausal 
patients with symptomatic VVA.33 Inclusion criteria stipu-
lated that patients must have 5% superficial cells on vaginal 
smear, a vaginal pH5 and at least one most bothersome 
symptom. Patients were randomized to treatment with either 
placebo or ospemifene (30 mg or 60 mg) given once daily for Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
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12 weeks. At the end of treatment, patients were given the 
option of entering the long-term safety extension study. In 
accordance with FDA guidance, all patients were provided 
vaginal lubricant to use as needed. The four co-primary 
endpoints discussed earlier were analyzed using previously 
agreed upon statistical methods with the FDA. Due to the 
inclusion of more than one dose, efficacy had to be evalu-
ated using a step-down approach. Specifically, statistical 
significance had to be observed at the 60 mg dose before the 
30 mg dose could be considered. Likewise, the multiplicity of 
VVA symptom evaluation was addressed with a step-down 
procedure, where statistically significant improvement in 
vaginal dryness had to be demonstrated before dyspareunia 
could be evaluated. Routine adverse event monitoring, stan-
dard laboratory assessments and evaluations of endometrial 
thickness, and histology by biopsy were performed.
The results showed that ospemifene was well toler-
ated, with 86%, 80%, and 85% of patients completing the 
study in the placebo and the 30 mg and 60 mg ospemifene 
groups, respectively. Treatment emergent adverse events 
were similar in all groups. Serious adverse events were 
reported in nine patients (four patients in the placebo group, 
five patients at 30 mg ospemifene, and none at the 60 mg 
dose). The most common adverse event was hot flashes, 
which had an incidence of 3% in the placebo group, 10% 
in the ospemifene 30 mg group, and 8% in the ospemifene 
60 mg group. Few patients experienced severe hot flashes 
or discontinued because of hot flashes, but the 30 mg dose 
appeared slightly worse than either the placebo or the 60 mg 
dose of ospemifene. Urinary tract infections were slightly 
more prevalent in the ospemifene-treated groups, which may 
have been related to a higher frequency of sexual activity. 
Endometrial thickness differed by 1 mm between the three 
treatment groups at the end of the 12-week treatment period, 
and no cases of endometrial hyperplasia were observed in any 
group. The efficacy of ospemifene was clearly demonstrated 
by all objective measures. Compared to placebo (+2%), the 
percentage of superficial cells was significantly increased by 
ospemifene treatment at both the 30 mg (+8%) and 60 mg 
doses (+11%). Parabasal cells were significantly decreased at 
both 30 mg (-22%) and 60 mg (-30%) ospemifene compared 
to a 4% increase in the placebo group. Ospemifene treatment 
also resulted in significant decreases in vaginal pH, with the 
30 mg and 60 mg doses decreasing pH by 0.7 and 1.0 points, 
respectively, compared to a decrease of 0.1 point in placebo-
treated patients.33
The two most bothersome symptoms that occurred fre-
quently enough for analysis were dyspareunia (46%) and 
vaginal dryness (39%). Ospemifene treatment resulted in 
significant improvement in these symptoms, particularly at 
the 60 mg dose. After 12 weeks of treatment, the vaginal 
dryness symptom score decreased significantly by 1.22 and 
1.26 points in the 30 mg and 60 mg groups, respectively, 
compared to a decrease of 0.84 points in the placebo group. 
Likewise, ospemifene treatment decreased dyspareunia 
symptom scores by 1.19 and 1.02 points at the 60 mg and 
30 mg doses, respectively, compared to a 0.89-point decrease 
in the placebo group. Though the decrease at both ospemifene 
doses exceeded that in the placebo group, the difference 
reached significance only at the 60 mg dose. Each symptom 
was assessed on a four-point scale specified as none (0), 
mild (1), moderate (2), or severe (3). Approximately 30% of 
women used lubricant at the beginning of the study. Lubricant 
use decreased in all groups as the study progressed, with the 
decrease being greater in the active treatment groups.33
Second pivotal Phase III trial (dyspareunia)
Based on the results of the first pivotal Phase III study as 
well as the Phase I and Phase II studies showing inferior-
ity of the 30 mg dose, the second pivotal Phase III study 
(both the dyspareunia and vaginal dryness substudies) 
compared 60 mg ospemifene to placebo.34,35 As in the first 
pivotal Phase III study, lubricants were provided to all study 
participants. Since the only VVA symptoms that occurred 
frequently enough to be effectively studied were vaginal 
dryness and dyspareunia, these symptoms were analyzed in 
separate studies. The Female Sexual Satisfaction Survey, a 
standardized scale used to evaluate quality of life improve-
ments, was also included. Other than these modifications, 
the two additional Phase III studies, one in dyspareunia34 and 
one in vaginal dryness,35 were identical to the first pivotal 
Phase III trial. These 12-week studies were conducted in 
parallel and evaluated the safety and efficacy of ospemifene 
60 mg compared to placebo using the same measures as in 
the first pivotal Phase III study.
The dyspareunia study randomized 605 postmenopausal 
patients with a diagnosis of VVA who self-identified a most 
bothersome symptom of dyspareunia for treatment with 
either placebo or ospemifene 60 mg.34 Efficacy was again 
clearly demonstrated by significant improvement in all four 
co-primary endpoints. The decrease in the percentage of 
parabasal cells, the increase in the percentage of superficial 
cells, the decrease in vaginal pH, and the decrease in the 
severity of dyspareunia symptoms were similar to previous 
studies and were highly significantly different compared to 
placebo. As in the first Phase III study, lubricant use was Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1945
Ospemifene for the treatment of dyspareunia
similar in the two groups early in the study and decreased 
during treatment in both groups, more so with ospemifene 
treatment than placebo. The drug was again well tolerated, 
with more ospemifene-treated patients (92%) completing 
the study compared to placebo-treated patients (88%), but 
a slightly higher percentage of ospemifene-treated patients 
(4.6%) than placebo-treated patients (3.3%) discontinuing 
because of adverse events. There were no treatment-related 
serious adverse events reported in either group. The most 
frequent adverse events in the ospemifene group were hot 
flashes (6.6% vs 4.3% in placebo) and urinary tract infec-
tions (5.6% vs 3.6% in placebo). Endometrial thickness 
increased slightly more with ospemifene treatment (0.4 mm) 
compared to placebo (0.1 mm), but no cases of hyperplasia 
were observed.34
Second pivotal Phase III trial (vaginal dryness)
The vaginal dryness study randomized 314 postmenopausal 
patients with a diagnosis of VVA and a self-identified most 
bothersome symptom of moderate-to-severe vaginal dryness 
to treatment with either 60 mg ospemifene or placebo daily 
for 12 weeks.35 All three objective measures of efficacy 
were significantly improved with ospemifene treatment. The 
decrease in the percentage of parabasal cells, the increase in 
the percentage of superficial cells, and the decrease in vaginal 
pH were similar to previous studies and were highly signifi-
cant compared to placebo. Improvement in vaginal dryness 
was greater in the ospemifene-treated group (-1.3) than the 
placebo-treated group (-1.1), but the intent-to-treat analysis 
with the last visit carried forward for missing data, which is 
required for regulatory approval, fell short of statistical sig-
nificance. The more clinically relevant per protocol analysis, 
which included only patients who had completed 10 weeks 
of treatment with 85% compliance, showed significantly 
greater improvement with ospemifene (-1.4) compared 
to placebo (-1.1). There were also greater proportions of 
patients describing either no or mild vaginal dryness (30% 
vs 23%) and patients improving by two to three levels in 
the symptom score (50% vs 34%) in the ospemifene-treated 
group compared to placebo-treated group. The safety profile 
in this study was similar to that previously reported. Hot 
flashes and urinary tract infections were the most frequent 
adverse events. Serious adverse events were similar in the 
two groups, but there was one case of deep vein thrombosis 
in the ospemifene group that was considered possibly related 
to treatment. Endometrial thickening was more evident in the 
ospemifene group than the placebo group, but no hyperplasia 
was reported.35
Phase III long-term safety
For endometrial safety, FDA guidance required that 
100–200 patients be treated at the intended dose for 1 year, 
with endometrial biopsies confirming 1% hyperplasia 
with 95% confidence. Some long-term safety data with 
endometrial biopsies were obtained from the long-term 
safety extension of the first pivotal Phase III trial,36,37 but 
in order to reach the required 1-year exposure, a dedicated 
Phase III long-term safety study was initiated.38 This 
study randomized postmenopausal women with a diagno-
sis of VVA and an intact uterus to treatment with 60 mg 
ospemifene or placebo daily for 12 months using a 6:1 
randomization schedule. Safety assessments included endo-
metrial biopsy, endometrial thickness, and breast and gyne-
cological exams. Efficacy at 12 weeks was also examined 
with vaginal maturation index and vaginal pH, but unlike 
previous studies there was no assessment of symptomatic 
efficacy. Out of the 426 patients randomized, 363 patients 
received ospemifene and 63 patients received placebo. 
A total of 349 patients completed the study: 294 patients in 
the ospemifene group and 55 patients in the placebo group. 
After 12 weeks of treatment, changes in the objective mea-
sures of efficacy including the decrease in parabasal cells, 
increase in superficial cells, and decrease in vaginal pH 
were similar in magnitude to those previously observed and 
were highly significant.38 Visual evaluation of the vagina 
at 52 weeks of treatment showed significant improvement 
in petechiae, pallor, friability, vaginal dryness, and vaginal 
redness in patients treated with 60 mg ospemifene compared 
to placebo.38 Safety outcomes are presented in the “Com-
prehensive clinical safety summary” section.
Phase III VVA efficacy summary
A summary of ospemifene’s efficacy as assessed by vaginal 
maturation index, vaginal pH, and VVA symptom relief 
from the Phase III trials is presented in Tables 1 and 2. The 
objective measures were all consistently positive and highly 
statistically significant in all four Phase III studies in which 
they were assessed.33–35,38 Although changes in the vaginal 
maturation index and vaginal pH were significant at the 30 
mg dose, the magnitude was less than that observed at 60 
mg. Parabasal cells decreased 30%–40% at the 60 mg dose, 
with small and inconsistent changes in the placebo group 
(Table 1). Superficial cells increased 5%–10% with little if 
any change in the placebo group. Vaginal pH decreased by 
about one point at the 60 mg dose (Table 2). As assessed 
by these measures, efficacy continued through 1 year of 
treatment.38Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
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With respect to symptomatic relief of dyspareunia and 
vaginal dryness as measured on the four-point scale, the 
60 mg dose proved to be superior compared to placebo and 
30 mg ospemifene. For dyspareunia, symptomatic relief was 
significant at the 60 mg dose in both the pivotal Phase III 
studies.33,34 The 30 mg dose was better than placebo, but 
the change failed to reach statistical significance (Table 2). 
The number of patients who experienced an improvement 
in symptom score of at least two points was higher with 
60 mg ospemifene than either placebo or 30 mg ospemifene.33 
Symptomatic improvement in patients with vaginal dryness 
was significantly better at both 30 mg and 60 mg ospemifene 
in the first pivotal Phase III trial (Table 2).33 This was true 
when measured by either the average on the four-point 
symptom scale or the number of patients experiencing 
improvement of at least two points on the scale. In the patients 
included in the Phase III vaginal dryness trial, the magnitude 
of symptom improvement was similar to the dyspareunia 
study, but by intent-to-treat analysis, it fell slightly short of 
statistical significance. In the more clinically relevant per 
protocol analysis, the difference was significant (Table 2).35 
Other secondary analyses of efficacy in this group such as 
number of responders, number of patients showing at least 
two levels of improvement, and the number of patients 
experiencing complete symptom relief all supported the 
conclusion that vaginal dryness was indeed effectively treated 
in this study.35
Comprehensive clinical safety summary
Unlike efficacy, which is best evaluated by considering the 
results of individual studies that are designed and statistically 
powered to show clinical effects, drug safety is better assessed 
as a reflection of the total exposures from all studies combined. 
A total of 1,892 patients were exposed to ospemifene during 
the Phase II and Phase III studies, with an average duration 
of exposure of 182 days. This represents approximately 1,000 
patient years of exposure under monitored conditions, the 
majority of which occurred at the 60 mg dose. A patient year 
is the exposure of one patient to the study drug for 1 year at the 
prescribed dosing schedule. More than 400 patients exceeded 
1 year of treatment with ospemifene. All patients included 
in the ospemifene Phase II and Phase III clinical trials were 
postmenopausal with an average age of 59 years, and 86% 
were on concomitant medications.
In the clinical studies, no clinically significant changes in 
routine safety assessments, including hematology, chemistry, 
and urinalysis, were observed. The most common treat-
ment emergent adverse events at the 60 mg dose were hot 
flashes (7.5% vs 2.6% placebo), vaginal discharge (3.8% 
vs 0.3% placebo), muscle spasms (3.2% vs 0.9% placebo) 
Table 1 Phase III efficacy of ospemifene: vaginal maturation index
Study Parabasal cells (%∆)a Superficial cells (%∆)a Number of patients (n)
Placebo 30 mg 60 mg Placebo 30 mg 60 mg Placebo 30 mg 60 mg
First pivotal phase III33 4.0 -21.9b -30.1b 2.2 7.8b 10.8b 268 282 276
Phase III dyspareunia (ITT)34 0.0 – -40.2c 1.7 – 12.3c 302 – 303
Phase III dyspareunia (PP)34 -0.2 – -42.1c 1.9 – 13.2c 251 – 255
Phase III vaginal dryness (ITT)35 -3.9 – -31.7b 0.0 – 7.0b 154 – 160
Phase III vaginal dryness (PP)35 -4.7 – -36.6b 0.0 – 8.0b 137 – 127
Phase III long-term safety38 0 – -40c 0 – 5c 63 – 363
Notes: aBaseline to week 12. bP0.001 compared to placebo. cP0.0001 compared to placebo.
Abbreviations: ITT, intent to treat; PP, per protocol.
Table 2 Phase III efficacy of ospemifene: vaginal pH and symptoms of vulvar and vaginal atrophy
Study Vaginal pH (∆)a Most bothersome symptom (∆)a Number of patients (n)
Placebo 30 mg 60 mg Placebo 30 mg 60 mg Placebo 30 mg 60 mg
First pivotal phase III33 -0.10 -0.67b -1.01b -0.84c/ 
-0.89d
-1.22b,c/ 
-1.02d
-1.26b,c/ 
-1.19d,e
268 282 276
Phase III dyspareunia (ITT)34 -0.07 – -0.94f -1.2 – -1.5f 302 – 303
Phase III dyspareunia (PP)34 -0.08 – -1.1f -1.2 – -1.6g 251 – 255
Phase III vaginal dryness (ITT)35 -0.25 – -0.95b -1.1 – -1.3 154 – 160
Phase III vaginal dryness (PP)35 -0.23 – -0.99b -1.1 – -1.4h 137 – 127
Notes:  aFrom baseline to 12 weeks.  bP0.001 compared to placebo.  cvaginal dryness.  dDyspareunia.  eP=0.023 compared to placebo.  fP0.0001 compared to placebo. 
gP=0.0004 compared to placebo. hP=0.014 compared to placebo.
Abbreviations: ITT, intent to treat; PP, per protocol.Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
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and headache (2.4% incidence with both ospemifene and 
placebo).39 Although vasomotor symptoms were more com-
mon in ospemifene-treated patients, the symptoms were well 
tolerated and rarely led to study discontinuation.38 Urinary 
tract infections were also more common in ospemifene-
treated patients, particularly early in the trials. It has been 
speculated that this may be related to more frequent sexual 
activity, implying that the treatment was working, but this 
has not been confirmed.33 Urinary tract infections seemed to 
occur at similar rates in the ospemifene and placebo groups as 
treatment continued.37 All serious treatment emergent adverse 
events not necessarily related to drug treatment were slightly 
higher in patients treated with 60 mg ospemifene compared 
to placebo when evaluated by patient, but lower for 60 mg 
ospemifene than in the placebo patients when evaluated by 
exposure.36–38 No deaths occurred in any of the ospemifene 
clinical trials.
Of particular interest with SERMs is the frequency of car-
diovascular events. Six ospemifene-treated patients (0.3%) 
and one placebo-treated patient (0.1%) discontinued due to 
a cardiovascular event. For patients treated with ospemifene, 
these events included two deep vein thromboses, three 
cerebrovascular accidents (strokes), and one myocardial 
infarction that occurred in a patient who had pre-existing 
cardiovascular disease and a long history of type 2 diabe-
tes mellitus and hypertension.35,36,38 Of the three strokes in 
ospemifene-treated patients, one was not considered treat-
ment related.38 There were no cases of thromboembolism 
reported. Two cardiovascular events, a stroke, and a deep 
vein thrombosis, occurred in the placebo-treated patients.34,39 
The rate of occurrence of any cardiovascular event was 
approximately six per 1,000 patient years of treatment. The 
incidence of deep vein thrombosis was approximately 0.1% 
in ospemifene-treated patients, which is lower than that 
reported for recently approved SERMs, and was the same as 
that observed in the placebo-treated patients.39 The incidence 
of stroke in both ospemifene-treated and placebo-treated 
patients was also approximately 0.1%.38,39 No electrocardio-
gram changes were observed in patients taking ospemifene. 
A detailed clinical evaluation of the impact of ospemifene 
treatment, as required by the FDA, was negative.2
Endometrial safety was of course a major point of 
emphasis during the clinical development of ospemifene. 
Adverse estrogenic effects in the uterus have proven to be a 
major stumbling block in the development of new SERMs.40 
Transvaginal ultrasound before, during, and after treatment 
was used to monitor and detect changes in the endometrium. 
Compared to placebo, which showed no change, mean 
endometrial thickness increased by less than 1 mm during   
12 months of treatment with 60 mg ospemifene.38 The 
number of patients with endometrial thickening greater than 
8 mm at the end of 12 months of treatment was higher in 
ospemifene-treated patients (1.0%) compared to placebo-
treated patients (0%).37 No cases of endometrial hyperplasia 
or carcinoma were detected by biopsy at the end of 12 months 
of treatment.37 Although one patient did have a biopsy that 
showed endometrial hyperplasia without atypia 3 months 
after the last dose of ospemifene,38 one case in 347 biopsies 
after 12 months of treatment is well below the threshold for 
concern. Five patients who received 60 mg of ospemifene 
had an endometrial polyp on biopsy (1.4%), only one of 
which (0.3%) was confirmed to be a true polyp.38 Bleed-
ing or spotting occurred in 1.4% of patients with an intact 
uterus treated with ospemifene38 compared to 0.7% of similar 
placebo-treated patients.34
In postmenopausal women taking estrogen-based prod-
ucts for the treatment of menopausal symptoms, breast 
safety has become a key concern following the results of the 
Women’s Health Initiative trial of estrogen plus progestin.5 
After 1 year of treatment, ospemifene demonstrated a very 
good breast safety profile. While there were reports of breast 
tenderness, breast mass, and breast pain, the frequency 
was low, and similar to that which occurred in the placebo 
group.37,38 There were two cases of breast cancer reported in 
300 patient years of placebo treatment, which is a frequency 
that is to be expected in this population. Interestingly, in the 
805 patient years of treatment with ospemifene, no cases of 
breast cancer were reported,36–38 which is consistent with 
extensive preclinical data in rodent models of breast cancer 
showing that ospemifene is effective as a breast cancer 
chemopreventive agent, similar to tamoxifen.23,41–44
Discussion
Ospemifene, currently being sold under the trade name 
Osphena, is an SERM that was approved by the FDA in early 
2013 for the treatment of moderate-to-severe dyspareunia 
associated with VVA due to menopause. As the first non-
hormonal, non-estrogen agent approved for the treatment of 
this condition, ospemifene represents a significant milestone 
in postmenopausal women’s health, helping satisfy an unmet 
medical need for a non-hormonal alternative to estrogen-
based products, the use of which has been associated with 
increased risks of breast cancer, stroke, and cardiovascular 
disease,3,5,8,45,46 for the treatment of VVA symptoms. Among 
the different SERMs that have received FDA approval, which 
include tamoxifen, toremifene, raloxifene, and bazedoxifene Clinical Interventions in Aging 2014:9 submit your manuscript | www.dovepress.com
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(approved as a single agent only in the Europe), ospemifene 
is unique because it exerts a nearly full estrogen agonist 
effect in the vagina,20,21 making it an effective treatment for 
VVA symptoms,33–35,38 while tamoxifen may aggravate this 
condition.47 Although the FDA did not grant approval for 
the treatment of vaginal dryness, the close association of 
the symptoms of vaginal dryness and dyspareunia to VVA 
as documented by objective criteria and multiple parameter 
analyses that support efficacy in the treatment of vaginal 
dryness, there is little doubt that ospemifene is an effective 
treatment for vaginal dryness associated with VVA due to 
menopause.33,35
Data from multiple Phase III clinical trials have clearly 
demonstrated the efficacy of ospemifene in treating VVA as 
assessed by significant improvement in the vaginal matura-
tion index (increases in superficial cells and decreases in 
parabasal cells), significant decreases in vaginal pH, and sig-
nificant improvement in the self-identified most bothersome 
symptoms of dyspareunia and vaginal dryness.33–38 Based 
on the results of Phase III long-term safety studies showing 
that ospemifene has no clinically relevant estrogenic effects 
in the endometrium and a very low incidence of cardiovas-
cular events, similar to placebo, following daily treatment 
with 60 mg for 1 year, ospemifene is a safe alternative to 
estrogen-based products for the treatment of VVA due to 
menopause.37,38 Although vasomotor symptoms were more 
common in ospemifene-treated patients – hot flashes were 
the most frequently encountered adverse event – they were 
well tolerated and rarely led to study discontinuation.38 With 
regard to breast-related issues, ospemifene demonstrated a 
good safety profile. While some cases of breast tenderness 
and pain were observed, the incidence was low and not sig-
nificantly different from placebo.37,38 Most importantly, no 
cases of breast cancer were seen in the ospemifene-treated 
patients.36–38
Interestingly, at the time ospemifene was approved, the 
FDA required that its labeling include a boxed warning 
similar to estrogen-based products, a warning considered 
unwarranted by some,48 as well as a warning against its use 
in women who have or may develop breast cancer.39 While 
it is true that ospemifene does exert a slight estrogenic 
effect in the endometrium, published preclinical and clinical 
data show that the magnitude of this effect is far less than 
that of steroidal estrogen and was found to be clinically 
insignificant.20,21,23,49–52 Furthermore, following 52 weeks 
of daily treatment with 60 mg, the effects of ospemifene in 
the endometrium, based on histology and ultrasonography 
results, appeared to be more similar to the SERM raloxifene 
than to estrogen.49 With regard to the breast cancer warning, it 
is true that the currently available clinical data are insufficient 
to make any claim that ospemifene has beneficial effects in 
either the treatment or prevention of breast cancer; however, 
there are no clinical data showing that ospemifene would 
increase the risk of breast cancer either. In fact, virtually all 
data generated to date suggest that ospemifene, similar to 
other FDA-approved SERMs, acts as an antiestrogen in breast 
tissue and is more likely to have beneficial than detrimental 
effects.44 Further clinical study is needed to establish the 
breast safety of ospemifene and to assess its potential as a 
breast cancer chemopreventive agent.
Conclusion
Ospemifene is an SERM that was approved by FDA in 
2013 for the treatment of moderate-to-severe dyspareunia 
associated with VVA due to menopause, making it the first 
non-hormonal agent to receive such approval. The results 
of several Phase III clinical trials have clearly demonstrated 
that ospemifene is highly effective in improving the vaginal 
maturation index, decreasing vaginal pH, and treating the 
most bothersome symptoms of dyspareunia and vaginal 
dryness. Ospemifene possesses a nearly full estrogen agonist 
effect in the vaginal epithelium, making it uniquely suited 
among the currently approved SERMs for the treatment of 
VVA in postmenopausal women. Long-term safety studies 
have established that while ospemifene does exert a slight 
estrogenic effect in the endometrium, this effect is clinically 
insignificant and similar to that of the SERM raloxifene. Hot 
flashes were the most common side effect seen in clinical 
trials, but they were well tolerated and mostly mild to mod-
erate in severity. Ospemifene demonstrated a good breast 
safety profile, and the incidence of cardiovascular events 
was similar to placebo. Thus, ospemifene appears to be a 
safe and effective alternative to estrogen-based products for 
the treatment of VVA-related symptoms.
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